The extraordinary hope of antiretroviral therapy in South Africa (even for patients with tuberculosis or kaposi sarcoma!)

Journal of Infectious Diseases

Volumn 191, Issue 3, 2005, Pages 321-323

  Flanigan, Timothy P ^a,d   Campbell, Thomas ^b   Harwell, Joseph ^a   Kumarasamy, N ^c  

^a MIRIAM HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c VHS Medical Centre India   (India)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; COMORBIDITY; CULTURAL ANTHROPOLOGY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIET; EDITORIAL; GENETICS; HEALTH EDUCATION; HEALTH PRACTITIONER; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SOUTH AFRICA; T LYMPHOCYTE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MYCOBACTERIUM TUBERCULOSIS; REVERSE TRANSCRIPTASE INHIBITORS; SARCOMA, KAPOSI; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 12344314153     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427341     Document Type: Editorial

References (17)

1. Cassol E, Page T, Mosam A, et al. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J Infect Dis 2005; 191:324-32 (in this issue).
2. Yeni G, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
3. Steinbrook R. The AIDS epidemic in 2004. N Engl J Med 2004; 351:115-20.
4. Laurent C, Kouanfack, C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stuavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34.
5. Kumarasamy N, Solomon S, Chaguturu SK, et al. Safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in South India. AIDS 2003; 17:2267-9.
6. Kumarasamy N, Flanigan T, Solomon S, et al. Rapid viral load suppression following generic HAART in southern Indian HIV-infected patients [abstract ThPeB7137]. In: Programs and abstracts of the XV International AIDS Conference (Bangkok). MedGenMed 2004; 6: ThPeB7137
7. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95.
8. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Afrida. AIDS 2003; 17:1369-75.
9. Henry K, Brundage R, Weller D, Akinsete O, Shet A. A comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets. J Acquir Immune Defic Syndr 2004; 35:537.
10. Penzak SR, Acosta EP, Turner M, Tavel JA, Masur H. Antiretroviral drug content in products from developing countries. Clin Infect Dis 2004; 38:1317-19.
11. Kumarasamy N, Solomon S, Purnima M, et al. High plasma viral load in persons co-infected with HIV and tuberculosis in South India [abstract 78.022]. Program and abstracts of the 9th International Congress on Infectious Diseases (Buenos Aires). Boston: International Society for Infectious Diseases, 2000.
12. Manosuthi W, Sungkanuparph S, Vibhagool A, et al. A randomized controlled trial of efavirenz 600 mg/day versus 800 mg/day in HIV-infected patients with tuberculosis to study plasma efavirenz level, virological and immunological outcomes: a preliminary result [abstract MoOrB1013]. In: Programs and abstracts of the XV International AIDS Conference (Bangkok). MedGenMed 2004; 6: MoOrB1013.
13. Kumarasamy N. Generic antiretroviral drugs-will they be the answer to HIV in the developing world? Lancet 2004; 364:3-4.
14. Voelker R. Conquering HIV and stigma in Kenya, JAMA 2004; 292:157-9.
15. Kumarasamy N, Flanigan TP, Mahajan AP, Carpenter CCJ, Mayer KH, Solomon S. Monitoring HIV treatment in the developing world: reflection and reaction. Lancet Infect Dis 2002; 2:656-7.
16. Mahajan AP, Hogan JW, Snyder B, et al. Changes in total lymphocyte count (TLC) as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. JAIDS 2004; 36:567-75.
17. Kumarasamy N, Mahajan A, Flanigan T, et al. The total lymphocyte count (TLC) is a useful tool for opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 2002; 31: 378-83.